Skip to main
LNTH

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 33%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings is poised for growth with its diverse portfolio of radiopharmaceutical products that address unmet needs in the cardiology and oncology markets. The recent FDA approval of PYLARIFY TruVu, along with the upcoming PDUFA decision for MK6240, provide strong catalysts for future revenue growth. The company has a solid commercial footprint and utilizes strategic partnerships to enhance its portfolio, positioning it for long-term success. Given its strong financial performance in the first quarter and a favorable market outlook, Lantheus Holdings has the potential to deliver strong returns for investors.

Bears say

Lantheus Holdings is a high-risk investment due to its heavy reliance on a single product, Pylarify, for revenue. Despite its recent revenue and earnings beat, the company faces declining prices and volumes for Pylarify and has yet to receive significant credit for its pipeline in the Alzheimer's diagnostic market. While it has multiple agents in development, commercialization is dependent on the availability of therapeutic agents, and any potential revenue contribution is still a few years out. Additionally, the company is facing patent litigation and has some upcoming PDUFA decisions, adding to its already high-risk profile.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 33% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.